Mer receptor tyrosine kinase is a therapeutic target in pre–B-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 85%. However, alterations to treatment strategies using available drugs are unlikely to provide significant improvement in survival or decrease therapy-associated toxicities. Here...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Linger, Rachel M. A., Lee-Sherick, Alisa B., DeRyckere, Deborah, Cohen, Rebecca A., Jacobsen, Kristen M., McGranahan, Amy, Brandão, Luis N., Winges, Amanda, Sawczyn, Kelly K., Liang, Xiayuan, Keating, Amy K., Tan, Aik Choon, Earp, H. Shelton, Graham, Douglas K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3757372/
https://ncbi.nlm.nih.gov/pubmed/23861246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-478156
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados